Sign up to access all valuation multiples
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company’s distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
1967
1.3K+
LTM Revenue $141M
LTM EBITDA $41.0M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Procter & Gamble Health has a last 12-month revenue (LTM) of $141M and a last 12-month EBITDA of $41.0M.
In the most recent fiscal year, Procter & Gamble Health achieved revenue of $129M and an EBITDA of $34.5M.
Procter & Gamble Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Procter & Gamble Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $141M | XXX | $129M | XXX | XXX | XXX |
| Gross Profit | $101M | XXX | $88.2M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $41.0M | XXX | $34.5M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $40.0M | XXX | $32.0M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $30.3M | XXX | $23.0M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Procter & Gamble Health's stock price is INR 6364 (or $73).
Procter & Gamble Health has current market cap of INR 106B (or $1.2B), and EV of INR 104B (or $1.2B).
See Procter & Gamble Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.2B | XXX | XXX | XXX | XXX | $1.82 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Procter & Gamble Health has market cap of $1.2B and EV of $1.2B.
Procter & Gamble Health's trades at 9.0x EV/Revenue multiple, and 33.2x EV/EBITDA.
Equity research analysts estimate Procter & Gamble Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Procter & Gamble Health has a P/E ratio of 40.0x.
See valuation multiples for Procter & Gamble Health and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 8.4x | XXX | 9.0x | XXX | XXX | XXX |
| EV/EBITDA | 29.0x | XXX | 33.2x | XXX | XXX | XXX |
| EV/EBIT | 29.7x | XXX | 36.6x | XXX | XXX | XXX |
| EV/Gross Profit | 11.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 40.0x | XXX | 50.8x | XXX | XXX | XXX |
| EV/FCF | 39.9x | XXX | 51.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialProcter & Gamble Health's last 12 month revenue growth is 14%
Procter & Gamble Health's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $42K for the same period.
Procter & Gamble Health's rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Procter & Gamble Health's rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Procter & Gamble Health and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | 41% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $42K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Procter & Gamble Health acquired XXX companies to date.
Last acquisition by Procter & Gamble Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Procter & Gamble Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Procter & Gamble Health founded? | Procter & Gamble Health was founded in 1967. |
| Where is Procter & Gamble Health headquartered? | Procter & Gamble Health is headquartered in India. |
| How many employees does Procter & Gamble Health have? | As of today, Procter & Gamble Health has 1.3K+ employees. |
| Is Procter & Gamble Health publicy listed? | Yes, Procter & Gamble Health is a public company listed on BOM. |
| What is the stock symbol of Procter & Gamble Health? | Procter & Gamble Health trades under 500126 ticker. |
| When did Procter & Gamble Health go public? | Procter & Gamble Health went public in 1992. |
| Who are competitors of Procter & Gamble Health? | Similar companies to Procter & Gamble Health include e.g. Acme United, EZZ Life Science, Lavipharm, Sarantis Group. |
| What is the current market cap of Procter & Gamble Health? | Procter & Gamble Health's current market cap is $1.2B |
| What is the current revenue of Procter & Gamble Health? | Procter & Gamble Health's last 12 months revenue is $141M. |
| What is the current revenue growth of Procter & Gamble Health? | Procter & Gamble Health revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Procter & Gamble Health? | Current revenue multiple of Procter & Gamble Health is 8.4x. |
| Is Procter & Gamble Health profitable? | Yes, Procter & Gamble Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Procter & Gamble Health? | Procter & Gamble Health's last 12 months EBITDA is $41.0M. |
| What is Procter & Gamble Health's EBITDA margin? | Procter & Gamble Health's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Procter & Gamble Health? | Current EBITDA multiple of Procter & Gamble Health is 29.0x. |
| What is the current FCF of Procter & Gamble Health? | Procter & Gamble Health's last 12 months FCF is $29.8M. |
| What is Procter & Gamble Health's FCF margin? | Procter & Gamble Health's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Procter & Gamble Health? | Current FCF multiple of Procter & Gamble Health is 39.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
